GlassScriptPhysician profile
Eric J Knaake
NPI 1952840241
$4,058.23
in general payments reported to CMS, 2019-2025
32 companies · $1,290 in 2025
The $1,290 reported for 2025 was more than what 90% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $459 · 2022: $577 · 2023: $657 · 2024: $1,075 · 2025: $1,290.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,986 · Debt Forgiveness: $35.61.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,986.34 |
| Debt Forgiveness | $35.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,701.34 | 2021-2025 | |
| Pfizer INC. | $540.93 | 2023-2025 | |
| Sk Life Science, INC. | $265.58 | 2022-2025 | |
| Ucb, INC. | $150.73 | 2024-2025 | Rystiggo, Nayzilam, Fintepla |
| Biohaven Pharmaceutical Holding Company LTD. | $135.95 | 2022 | |
| Lilly USA, LLC | $113.90 | 2023-2025 | Kisunla, Emgality, Amyvid |
| Lundbeck LLC | $112.05 | 2023-2025 | Vyepti |
| Supernus Pharmaceuticals, INC. | $107.80 | 2025 | Qelbree |
| Alexion Pharmaceuticals, INC. | $101.58 | 2025 | Ultomiris |
| Catalyst Pharmaceuticals, INC. | $77.21 | 2025 | |
| Biogen, INC. | $73.40 | 2022-2024 | Vumerity, Tysabri |
| Argenx US, INC. | $72.87 | 2024-2025 | Vyvgart Hytrulo, Vyvgart |
| Amgen INC. | $65.30 | 2021-2023 | Aimovig |
| Xeris Pharmaceuticals, INC. | $45.44 | 2024 | Keveyis |
| Alnylam Pharmaceuticals INC. | $42.97 | 2023-2024 | Onpattro |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurelis, INC. | $41.11 | 2024 | Valtoco |
| Tg Therapeutics, INC. | $40.23 | 2024 | |
| Baxter Healthcare | $35.61 | 2023-2024 | |
| Celgene Corporation | $34.88 | 2021-2025 | Zeposia |
| Livanova USA, INC. | $33.99 | 2024 | Vns Therapy Sentiva Model 1000 Generator |
| Vanda Pharmaceuticals INC. | $33.12 | 2025 | Ponvory |
| Takeda Pharmaceuticals U.S.A., INC. | $31.54 | 2025 | Hyqvia |
| Jazz Pharmaceuticals INC. | $27.47 | 2025 | |
| Ptc Therapeutics, INC. | $23.59 | 2021 | |
| Impel Pharmaceuticals INC. | $23.17 | 2023 | Trudhesa |
| Medtronic, INC. | $21.48 | 2023 | Percept PC Brainsense |
| Tanabe Pharma America, INC. | $20.95 | 2024 | |
| Acadia Pharmaceuticals INC | $20.64 | 2025 | Nuplazid |
| Merz Pharmaceuticals, LLC | $20.14 | 2025 | Xeomin |
| Neurocrine Biosciences, INC. | $15.70 | 2025 | |
| Biohaven Pharmaceuticals, INC. | $14.50 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $13.06 | 2023 | Austedo Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Knaake listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.